# Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder

> **NCT00374920** · PHASE2 · COMPLETED · sponsor: **Memory Pharmaceuticals** · enrollment: 60 (—)

## Conditions studied

- Bipolar Disorder With Manic or Mixed Episodes

## Interventions

- **DRUG:** MEM 1003

## Key facts

- **NCT ID:** NCT00374920
- **Lead sponsor:** Memory Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2006-12
- **Final completion:** 2007-03
- **Target enrollment:** 60 (—)
- **Last updated:** 2008-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00374920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00374920, "Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00374920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*